Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.35 |
| ▸ | CBS | P35520 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27297810 | 0.86 | CES2 (0.41) | CES2TSHRCTHCBSTHPO | |
| SCHEMBL3974164 | 0.79 | LMNA (0.35) | TSHRHDAC1HDAC2 | |
| SCHEMBL9969950 | 0.79 | CES2 (0.47) | CES2 | |
| SCHEMBL12516790 | 0.79 | CES2 (0.38) | CES2 | |
| SCHEMBL7939677 | 0.79 | THRB (0.35) | CES2TSHRCTHCBSTHPO | |
| SCHEMBL5346541 | 0.77 | ALDH1A1 (0.38) | CES2TSHRCTHCBSTHPO | |
| SCHEMBL4853751 | 0.77 | ALDH1A1 (0.38) | CES2TSHRCTHCBSTHPO | |
| SCHEMBL5355131 | 0.77 | ALDH1A1 (0.38) | CES2TSHRCTHCBSTHPO | |
| SCHEMBL5375976 | 0.77 | THRB (0.39) | CES2TSHRSMN1; SMN2THRB | |
| SCHEMBL19049755 | 0.77 | THRB (0.39) | CES2TSHRSMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174886-B1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| CN-106661043-B | 2-oxa-5-azabicyclo [2.2.1] hept-3-yl derivatives | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| US-9790230-B2 | 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3174886-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016015333-A1 | 2-OXA-5-AZABICYCLO [2.2.1] HEPTAN-3-YL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016016292-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| EP-2316827-B1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7754711-B2 | Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders | XENON PHARMACEUTICALS INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| WO-2009106991-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-09-03 | — | — | WO | disclosed |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| EP-1851205-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137435-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | HCRTR2, HCRTR1, CYP11B2 | CES2 170/4885TSHR 802/4885CTH 3598/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | CES2 2558/4885TSHR 697/4885CTH 3528/4885 |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | CES2 2305/4885TSHR 816/4885CTH 3568/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | CES2 2517/4885TSHR 693/4885CTH 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.